- 11-50 Employees
- Based in Melbourne, Australia
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle.
REPORT RATINGS4.8 / 5.0 (94)
Immuron Limited reports have an aggregate usefulness score of 4.8 based on 94 reviews.
Most Recent Annual Report
2020 Annual Report
Older/Archived Annual Reports